We are currently in a Phase 1/2b clinical trial of AMTX-100 CF as a potential best-in-class topical treatment for mild to moderate atopic dermatitis (eczema), an inflammatory skin disease affecting more than 31 million people in the U.S. alone. Atopic dermatitis, among other skin conditions, can be highly visible and cause mild to severe physical discomfort or disability, impacting nearly all aspects of a patient’s life. Amytrx’s FDA-approved pre-clinical studies in our atopic dermatitis IND cover several other inflammatory skin conditions, including psoriasis, rosacea, acne, herpes type 1 and 2, and shingles.
Amytrx's pre-clinical pipeline, supported by numerous animal studies of human disease, is focused on developing our lead compound AMTX-100 in a variety of formulations to enhance specificity and safety of therapeutic delivery—whether by systemic or high-concentration localized delivery—across a range of chronic inflammatory and autoimmune diseases.
AMTX-100 Formulations & Pipeline
We appreciate the role of volunteers who enroll in clinical trials—with their critical participation, we are able to evaluate and advance potential new therapies that can aid in restoring the health of millions of patients.
Amytrx has begun enrollment in an adaptive Phase 1/2b clinical trial of AMTX-100 CF in the skin disease, atopic dermatitis (eczema). For more information on this study, please visit clinicaltrials.gov.
Medical professionals can visit our contact page to email a request for more information about clinical trial participation.